Bibliography:

  1. ​ ‘GLP agonists’ tag

  2. ​ ‘semaglutide’ tag

  3. ​ Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

  4. ​ Tirzepatide for Obesity Treatment and Diabetes Prevention

  5. ​ Shady Drugmaker Used Code Words to Sell Knockoff Weight-Loss Drug Tirzepatide: Lawsuit

  6. ​ Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

  7. ​ Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

  8. ​ Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020–2023

  9. ​ Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

  10. ​ Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study

  11. ​ Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

  12. ​ A revolution in obesity treatment

  13. ​ Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same

  14. ​ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

  15. ​ Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

  16. ​ Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomized, phase 3 trial

  17. ​ Tirzepatide Once Weekly for the Treatment of Obesity

  18. ​ FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

  19. ​ Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1

  20. ​ Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial

  21. ​ Anti-obesity drug discovery: advances and challenges

  22. ​ Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicentre, phase 3 trial

  23. ​ Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial

  24. ​ Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]

  25. ​ Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial

  26. ​ Risk of Major Adverse Cardiovascular Events and All-Cause Mortality under Treatment With GLP-1 RAs or the Dual GIP/GLP-1 Receptor Agonist Tirzepatide in Overweight or Obese Adults without Diabetes: a Systematic Review and Meta-Analysis

  27. ​ Society Is Fixed, Biology Is Mutable

  28. ​ design#future-tag-features

    [Transclude the forward-link's context]

  29. ​ 2024-11-18-2024-packer-figure1-survivalanalysisoftirzepatideforheartfailurehalvesmortality.jpg

  30. ​ 2024-jastreboff-figure1-tirzepatidecausesweightlossandpreventsmostdiabetescases.jpg

  31. ​ 2024-malhotra-figure1-improvementinobesityandsleepapneafromtirzepatide.jpg

  32. ​ 2023-garvey-figure2-effectofweeklytirzepatideonweightloss.jpg

  33. ​ 2023-wadden-figure2-tirzepatideismuchmoreeffectivethandietandexerciseforsustainedweightloss.jpg

  34. ​ 2022-inagaki-figure3-effectoftirzepatideonbodyweight.jpg

  35. ​ https://biolabshop.eu/home-page/230-tirzepatide-5mg.html

  36. ​ https://clinicaltrials.gov/study/NCT04184622

  37. ​ https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight

  38. ​ https://marginalrevolution.com/marginalrevolution/2023/12/a-weighty-economics-puzzle.html#blog-comment-160691275

  39. ​ https://www.nature.com/articles/s42255-023-00811-0

  40. ​ A revolution in obesity treatment

  41. ​ %252Fdoc%252Flongevity%252Fglp%252Fsemaglutide%252F2023-lingvay.pdf.html

  42. ​ Goodbye, Ozempic: A new class of drugs is transforming obesity care. They are not all the same

  43. ​ https%253A%252F%252Fwww.theatlantic.com%252Fhealth%252Farchive%252F2023%252F06%252Fozempic-pills-obesity-drugs-semaglutide%252F674541%252F.html

  44. ​ FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

  45. ​ https%253A%252F%252Finvestor.lilly.com%252Fnews-releases%252Fnews-release-details%252Ffda-approves-lillys-mounjarotm-tirzepatide-injection-first-and.html

  46. ​ Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicentre, phase 3 trial

  47. ​ Julio Rosenstock

  48. ​ %252Fdoc%252Flongevity%252Fglp%252Ftirzepatide%252F2021-delprato.pdf.html

  49. ​ Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial

  50. ​ %252Fdoc%252Flongevity%252Fglp%252Ftirzepatide%252F2021-ludvik.pdf.html

  51. ​ Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]

  52. ​ Julio Rosenstock

  53. ​ %252Fdoc%252Flongevity%252Fglp%252Ftirzepatide%252F2021-frias.pdf.html

  54. Wikipedia Bibliography:

    1. ​ https://en.wikipedia.org/wiki/Glucose-dependent_insulinotropic_polypeptide

    2. ​ Glucagon-Like Peptide-1

    3. ​ Tirzepatide

    4. ​ Shubham Agarwal

    5. ​ Eli Lilly

    6. ​ Samir Arora

    7. ​ Ramon Reyes

    8. ​ Ahmed Arif

    9. ​ John O'Mahony

    10. ​ Bernhard Ludvik

    11. ​ Katelyn Brown